Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells

Biomedicine and Pharmacotherapy

Volumn 68, Issue 3, 2014, Pages 327-334

  Karthik, Selvaraju ^a   Sankar, Renu ^a   Varunkumar, Krishnamoorthy ^a   Ravikumar, Vilwanathan ^a  

^a BHARATHIDASAN UNIVERSITY   (India)

Author keywords

Bortezomib; NSCLC; Romidepsin

Indexed keywords

BORTEZOMIB; CELL CYCLE PROTEIN; GELATINASE A; GELATINASE B; HISTONE; HISTONE H3; HISTONE H4; PROTEIN P21; PROTEIN P53; ROMIDEPSIN; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; DEPSIPEPTIDE; HISTONE DEACETYLASE; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; PYRAZINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG POTENTIATION; ENZYME RELEASE; FLOW CYTOMETRY; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; ACETYLATION; CELL CYCLE CHECKPOINT; DRUG EFFECTS; GENETICS; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; TUMOR CELL LINE;

ACETYLATION; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DEPSIPEPTIDES; DRUG SYNERGISM; HISTONE DEACETYLASES; HISTONES; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PYRAZINES; UP-REGULATION;

EID: 84899486027     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.01.002     Document Type: Article

References (37)

1. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46:765-781.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
3. Aberle D.R., Adams A.M., Berg C.D., Black W.C., Clapp J.D., Fagerstrom R.M., et al. Reduced lung cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011, 365:395-409.
4. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
5. Kuo M.H., Allis C.D. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998, 20:615-626.
6. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation?. EMBO J 2000, 19:1176-1179.
7. Dominsgo-Domènech J., Pippa R., Tápia M., Gascón P., Bachs O., Bosch M. Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by Histone deacetylase inhibitors in human breast cancer cells. Breast Cancer Res Treat 2008, 112:53-62.
8. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005, 37:391-400.
9. Johnstone R.W. Histone deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002, 1:287-299.
10. Piekarz R.L., Frye R., Turner M., Wright J.J., Allen S.L., Kirschbaum M.H., et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009, 27:5410-5417.
11. McGraw A.L. Romidepsin for the treatment of T-cell lymphomas. Am J Health Syst Pharm 2013, 70:1115-1122.
12. Marks P., Rifkind R., Richon V., Breslow R., Miller T., Kelly W.K. Histone deacetylase and cancer. Nat Rev 2001, 1:194-202.
13. Denlinger C.E., Keller M.D., Mayo M.W., Broad R.M., Jones D.R. Combined histone deacetylation and proteosome inhibition enhances apoptosis in non-small cell lung cancer. J Thorac Cardiovasc Surg 2004, 127:1078-1086.
14. Mayo M.W., Denlinger C.E., Broad R.M., Yeung F., Reilly E.T., Shi Y., et al. Ineffectiveness of HDAC inhibitors to induce apoptosis involves the transcriptional activation of NF-κB through the Akt pathway. J Biol Chem 2003, 278:18980-18989.
15. Voorhees P.M., et al. The proteasome as a target for cancer therapy. Clin Cancer Res 2003, 9:6316-6325.
16. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003, 29:13-19.
17. Traenckner E.B., et al. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J 1994, 13:5433-5441.
18. Orlowski R.Z., Kuhn D.J. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008, 14:1649-1657.
19. Kane R.C., Dagher R., Farrell A., Ko C.W., Sridhara R., Justice R., et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007, 13:5291-5294.
20. John B.S., Zhong C., Gang D., et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001, 7:1419-1428.
21. Susin S.A., ZamZami N., Kroemer G. Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta 1998, 1366:151-165.
22. Jiang Y., Wang Y., Su Z., Yang L., Guo W., Liu W., et al. Synergistic induction of apoptosis in HeLa cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitor SAHA. Mol Med Rep 2010, 3:613-619.
23. Richardson P.G., Mitsiades C., Hideshima T., Anderson K.C., Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 2006, 57:33-47.
24. Yun D., Shuang C., Lora B.K., Vanessa L.F., Paul D., Steven G. Interactions between Bortezomib and Romidepsin and Belinostat in chronic lymphocytic leukemia cells. Clin Cancer Res 2008, 14:549-558.
25. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002, 7:9-16.
26. Carney D.N. Lung cancer-time to move on from chemotherapy. N Engl J Med 2002, 346:126-128.
27. Vigushin D.M., Coombes R.C. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 2002, 13:1-13.
28. Richon V.M., Sandhoff T.W., Rifkind R.A., Marks P.A. Histone deacetylase inhibitors selectively induces p21 WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 2000, 97:10014-10019.
29. Yu X., Guo Z.S., Marcu M.G., Neckers L., Nguyen D.M., Chen G.A., et al. Modulation of p53, ErbB1, ErbB2 and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002, 94:504-513.
30. Bernhard E.J., Gruber S.B., Muschel R.J. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci U S A 1994, 91:4293-4297.
31. Danø K., Rømer J., Nielsen B.S., Bjørn S., Pyke C., Rygaard J., et al. Cancer invasion and tissue remodeling - cooperation of protease systems and cell types. APMIS 1999, 107:120-127.
32. Iwata H., Kobayashi S., Iwase H., Masaoka A., Fujimoto N., Okada Y. Production of Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res 1996, 87:602-611.
33. Shuo C., Yang Z., Wen-feng G., Shuang Z., Yasuo T., Hua-chuan Z. The antitumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells. PLoS One 2013, 8:e79781.
34. Kwon S.H., Ahn S.H., Kim Y.K., Bae G.U., Yoon J.W., Hong S., et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 2002, 277:2073-2080.
35. Lin R.J., Nagy L., Inoue S., Shao W., Miller W.H., Evans R.M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998, 39:811-814.
36. Wu J.T., Archer S.Y., Hinnebusch B., Meng S., Hodin R.A. Transient vs. prolonged histone hyperacetylation: effects on colon cancer cell growth, differentiation, and apoptosis. Am J Physiol Gastrointest Liver Physiol 2001, 280:482-490.
37. Buggy J.J., Cao Z.A., Bass K.E., Verner E., Balasubramanian S., Liu L., et al. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther 2006, 5:1309-1317.